Streetwise Expert Interviews

Alan Leong

How Alan Leong of BioWatch News Keeps Successful Biotech Investing Simple

Biotechnology can be daunting to comprehend, but understanding is critical to successful investment. BioWatch News Founder Alan Leong has a nose for growth names, and his goal is to make their technology platforms clear to investors who might not be able to make sense of peer-reviewed scientific literature but want the big upside that science promises. In this interview with The Life Sciences Report, Leong brings seven micro-cap names with massive potential to investors' attention.

(3/4/15) More >
Read More Streetwise Interviews

How to Beat the Herd Mentality: Highline's Michael Higgins

Michael Higgins of Highline Research Advisors believes it is absolutely vital for a sellside biotech analyst to understand what's going on outside the sector, because no stock lives on an island. (2/25/15) More >

Newsletter Briefs

"CTRV's experienced management team knows how to present well, and investors are responding." (3/4/15) ContraVir Pharmaceuticals Inc. - The Life Sciences Report Interview with Alan Leong More >

"RP is going for a best-of-breed solution." (3/4/15) RepliCel Life Sciences Inc. - The Life Sciences Report Interview with Alan Leong More >

"Investors should keep a close eye on CBMG during 2015." (2/19/15) Cellular Biomedicine Group Inc. - The Life Sciences Report Interview with Stephen Dunn More >

"CANF's oral psoriasis candidate has shown some very, very promising data." (1/27/15) Can-Fite BioPharma Ltd. - The Life Sciences Report Interview with Reni Benjamin More >

"There is opportunity for the FDA to accept a new drug application filing from SNSS." (1/27/15) Sunesis Pharmaceuticals Inc. - The Life Sciences Report Interview with Mara Goldstein More >

"ATHX completed enrollment in its Phase 2 stroke study before the new year, so the first 90-day results will emerge in Q1/15E." (1/22/15) Athersys Inc. - The Life Sciences Report Interview with Edward Stopke More >

"The research synergy with Gilead and Merck could prove fruitful for RNN in terms of acquisition potential." (1/22/15) Rexahn Pharmaceuticals Inc. - The Life Sciences Report Interview with Edward Stopke More >

"If all goes well, CUR's NSI-189 product will move into Phase 2 development in Q2/15, so that is a good advancement opportunity." (1/22/15) Neuralstem Inc. - The Life Sciences Report Interview with Edward Stopke More >

Expert Analysis

"OMER looks well positioned for a solid gain." (3/3/15) Omeros Corp. - Zacks Equity Research More >

"ATHX and Chugai have announced a partnership for MultiStem." (3/2/15) Athersys Inc. - Henry McCusker, Regenerative Medicine Investors More >

"We are initiating coverage on CVM with a Buy rating." (3/2/15) CEL-SCI Corporation - Robert Wasserman, Dawson James Securities More >

"We are initiating coverage on NHC with a Buy recommendation." (2/26/15) Nobilis Health Corp. - Russell Stanley, Mackie Research Capital More >

"IPD is one of our High Conviction calls for 2015." (2/25/15) ImpediMed Ltd. - Scott Power, Morgans Financial Ltd. More >

"We expect OMER's Omidria (OMS302) to be launched soon." (3/2/15) Omeros Corp. - Jason Kolbert, Maxim Group More >

"Accelerating patient recuritment for CVM's Multikine Phase 3 study is a positive development." (3/4/15) CEL-SCI Corporation - Yale Jen, Laidlaw & Company More >

"ATHX's new partner, Chugai, is a highly experienced leader in Japan." (3/2/15) Athersys Inc. - Jason Kolbert, Maxim Group More >